Reply: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis
- PMID: 33737382
- DOI: 10.1183/13993003.00283-2021
Reply: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis
Conflict of interest statement
Conflict of Interest: J. Behr reports grants and personal fees from Boehringer Ingelheim, personal fees from Actelion, Roche, Galapagos, Promedior, BMS and MSD, during the conduct of the study. Conflict of Interest: D. Pittrow reports personal fees from Actelion, Bayer, Boehringer Ingelheim, Sanofi, Biogen, Shield and MSD, outside the submitted work. Conflict of Interest: J. Klotsche has nothing to disclose.
Comment on
-
Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.Eur Respir J. 2020 Aug 13;56(2):1902279. doi: 10.1183/13993003.02279-2019. Print 2020 Aug. Eur Respir J. 2020. PMID: 32381492
-
Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias?Eur Respir J. 2021 Mar 18;57(3):2004562. doi: 10.1183/13993003.04562-2020. Print 2021 Mar. Eur Respir J. 2021. PMID: 33737380 No abstract available.
-
Comment on: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis.Eur Respir J. 2021 Mar 18;57(3):2004645. doi: 10.1183/13993003.04645-2020. Print 2021 Mar. Eur Respir J. 2021. PMID: 33737381 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources